ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network
- None.
- None.
Insights
The partnership between ProteoNic Biosciences and Ginkgo Bioworks represents a strategic move within the biotechnology sector that could have a significant impact on the production capabilities of biologics and viral vectors. ProteoNic's vector technology facilitates the production of complex molecules that are traditionally challenging to express. This capability is crucial as biologics often involve the expression of proteins that require precise folding and post-translational modifications to be therapeutically effective.
By integrating ProteoNic's technology, Ginkgo Bioworks can potentially address production bottlenecks in lentiviral (LV) and adeno-associated viral (AAV) vectors, which are commonly used in gene therapies. The ability to increase yield and reduce costs in the manufacturing process is a critical factor for companies in the biotech industry, where production efficiency directly impacts the cost of goods sold (COGS) and, consequently, profit margins.
Furthermore, the inclusion of ProteoNic in the Ginkgo Technology Network signifies an expansion of Ginkgo's ecosystem, which could lead to enhanced R&D outcomes through collaborative innovation. This network effect can result in faster development cycles and potentially groundbreaking advancements in genetic medicines and biologics.
From a market perspective, the collaboration between ProteoNic Biosciences and Ginkgo Bioworks could position Ginkgo more competitively in the biotech market. Access to advanced vector technology is a key differentiator in the biologics and gene therapy space, where companies are constantly seeking to improve their production processes and reduce time-to-market for their products.
The partnership may also influence investor sentiment towards Ginkgo Bioworks, as strategic alliances often signal growth potential and technological advancements. It is important to monitor the stock market's reaction to such announcements, as they can lead to fluctuations in share prices based on perceived value creation. The long-term impact on Ginkgo's financial performance will depend on the successful integration and commercialization of ProteoNic's technology within Ginkgo's service offerings.
Additionally, the alliance could attract further interest from potential customers and partners, looking to leverage the combined expertise and technologies of both companies to enhance their own R&D capabilities and product development.
Examining the financial implications of the partnership, Ginkgo Bioworks stands to benefit from potential cost savings and increased revenue streams. ProteoNic's vector technology aims to reduce COGS by improving the efficiency of biologic production. This efficiency gain could lead to margin expansion for Ginkgo Bioworks if these savings are realized and passed on to customers in a competitive pricing strategy.
The strategic alliance should be evaluated in terms of return on investment (ROI) and how it aligns with Ginkgo Bioworks' overall financial strategy. Investors will be interested in how this partnership impacts Ginkgo's earnings, cash flow and market share within the biotech industry. The ability to provide novel viral vector technology for cell and gene therapy applications also opens up new revenue channels, which could be significant given the high growth potential of the gene therapy market.
It's essential to analyze the terms of the partnership, including any upfront payments, revenue-sharing agreements and long-term financial commitments, as these will influence the financial health of both companies involved.
LEIDEN, Netherlands , March 13, 2024 /PRNewswire/ -- ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications. This also marks ProteoNic's joining the Ginkgo Technology Network, a groundbreaking ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs.
"This collaboration opens a significant opportunity for ProteoNic and its customers," says Frank Pieper, ProteoNic's CEO. "This partnership seamlessly aligns with our core mission of supporting our clients in enabling production of complex biologics, driving capacity enhancements and achieving cost-of-goods savings in biologics manufacturing, while also tackling critical hurdles in viral vector manufacturing for cell and gene therapies."
ProteoNic's premium vector technology is broadly applicable across cell lines and product classes, including complex molecules which are difficult to express by conventional technology. Application of this novel technology enables production of complex molecules at economically viable levels, resolves capacity constraints and reduces manufacturing costs. Applied to viral vectors, it has the capacity to resolve bottlenecks currently associated with LV and AAV production.
The Ginkgo Technology Network brings together a diverse array of partners, spanning AI, genetic medicines, biologics, and manufacturing, with the aim of integrating their capabilities to provide customers with robust end-to-end solutions for successful R&D outcomes.
"I've known and admired the ProteoNic team for several years and am thrilled to welcome them to the Ginkgo Technology Network," said Anna Marie Wagner, Ginkgo's SVP, Head of AI and Corporate Development. "Their expertise and premium technology adds tremendous value to our network, enhancing our ability to provide comprehensive solutions to our customers across various biotech sectors."
About ProteoNic BV
ProteoNic is a privately held company with offices in Leiden,
For more information, see www.proteonic.nl.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit www.ginkgobioworks.com and www.concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.
For more information please contact:
ProteoNic BV
Mark Posno, PhD
Vice President Business Development
T: +1 617 480 8016
E: posno@proteonic.nl
Logo: https://mma.prnewswire.com/media/1804728/ProteoNic_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/proteonic-announces-partnership-with-ginkgo-bioworks-and-joins-the-ginkgo-technology-network-302087860.html
SOURCE ProteoNic
FAQ
What is the partnership between ProteoNic Biosciences and Ginkgo Bioworks about?
What benefits does ProteoNic's vector technology offer?
What is the Ginkgo Technology Network?
Who is Anna Marie Wagner and what is her role in the partnership?
